Imugene Limited (ASX:IMU) director Charles Walker has purchased 163,500 shares in the company for a consideration of 18 cents per share.
The indirect purchase by a director related entity brings Walker’s total securities to 28,350,710 (direct and indirect holdings).
Imugene is focused on developing immuno-oncology treatments CF33 and PD1-Vaxx in first-in-human studies as well as continued enrolment of its HER-Vaxx phase-2 study.
CF33 has been shown to efficiently shrink injected tumours and distant non-injected tumours in human triple-negative breast cancer, colon cancer, ovarian cancer xenograft models in mice without adverse effects.
The company’s PD1-Vaxx is a B-cell immunotherapy, peptide cancer vaccine designed to treat tumours such as lung cancer and will be trialled on patients in 2020.
HER-Vaxx is a therapeutic cancer vaccine for the treatment of gastric cancer and breast cancer with Phase 2 studies underway.